neoparin 100 mg/ml roztwór do wstrzykiwań
sciencepharma sp. z o.o. - enoxaparinum natricum - roztwór do wstrzykiwań - 100 mg/ml
neoparin forte 12 000 j.m. (120 mg)/0,8 ml roztwór do wstrzykiwań
sciencepharma sp. z o.o. - enoxaparinum natricum - roztwór do wstrzykiwań - 12 000 j.m. (120 mg)/0,8 ml
neoparin forte 15 000 j.m. (150 mg)/ml roztwór do wstrzykiwań
sciencepharma sp. z o.o. - enoxaparinum natricum - roztwór do wstrzykiwań - 15 000 j.m. (150 mg)/ml
neoparin multi 10 000 j.m. (100 mg)/ml roztwór do wstrzykiwań
sciencepharma sp. z o.o. - enoxaparinum natricum - roztwór do wstrzykiwań - 10 000 j.m. (100 mg)/ml
sulovas 250 lsu kapsułki miękkie
aflofarm farmacja polska sp. z o.o. - sulodexidum - kapsułki miękkie - 250 lsu
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - okulistyka - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - okulistyka - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - okulistyka - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
enoxaparin sodium ledraxen 4000 j.m. roztwór do wstrzykiwań w ampułko-strzykawce
venipharm - enoxaparinum natricum - roztwór do wstrzykiwań w ampułko-strzykawce - 4000 j.m.
enoxaparin sodium ledraxen 10 000 j.m. roztwór do wstrzykiwań w ampułko-strzykawce
venipharm - enoxaparinum natricum - roztwór do wstrzykiwań w ampułko-strzykawce - 10 000 j.m.